Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.

Company profile

Ticker

RIGL

Exchange

NASDAQ

Website

www.rigel.com

CEO

Raul Rodriguez

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...

SEC CIK

0001034842

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

IRS number

943248524

RIGL stock data

1M 1Y 5Y

News

From Benzinga Pro

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

3 Aug 22

Here's a roundup of top developments in the biotech space over the last 24 hours:

Rigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing Pact

3 Aug 22

Rigel Pharmaceuticals: Q2 Earnings Insights

2 Aug 22

Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Rigel Pharmaceuticals Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $29.80M Beat $23.65M Estimate

2 Aug 22

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study

2 Aug 22

Press releases

From Benzinga Pro

Thinking about buying stock in Advanced Micro Devices, Endo International, Faraday Future Intelligent Electric, Robinhood Markets, or Rigel Pharmaceuticals?

3 Aug 22

NEW YORK, Aug. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, ENDP, FFIE, HOOD, and RIGL.

Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update

2 Aug 22

Second quarter TAVALISSE® net product sales of $18.6 million and total revenues of $29.8 million Expanded Rigel's hematology-oncology portfolio by entering into an exclusive license agreement with Forma

Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia

2 Aug 22

Registrational Phase 2 data demonstrate olutasidenib's potential as a market-leading, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor for the treatment of relapsed or refractory acute myeloid leukemiaFDA

Rigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update

26 Jul 22

Thinking about buying stock in Energy Focus, Ford Motor, Clovis Oncology, Li Auto, or Rigel Pharmaceuticals?

22 Jun 22

Analyst ratings and price targets

Last 3 months

Average target

$3.01

Low target

$0.80

High target

$7.00

Calendar

2 Aug 22

12 Aug 22

31 Dec 22

Financial summary

Financial statements Chart RIGL financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	27.2M	27.2M	27.2M	27.2M	27.2M	27.2M
Cash burn (monthly)	(no burn)	4.8M	4.5M	7.06M	4.3M	5.66M
Cash used (since last report)	n/a	6.95M	6.51M	10.22M	6.23M	8.19M
Cash remaining	n/a	20.25M	20.69M	16.99M	20.97M	19.01M
Runway (months of cash)	n/a	4.2	4.6	2.4	4.9	3.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

RIGL insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
9 Jun 22	Raul R Rodriguez	Common Stock	Buy	Acquire P	No	No	0.6884	1,000,000	688.4K	1,391,776
20 May 22	Moos Walter H	Common Stock	Grant	Acquire A	No	No	0	25,000	0	52,222
20 May 22	Moos Walter H	Stock Option Common Stock	Grant	Acquire A	No	No	2.01	30,000	60.3K	30,000
20 May 22	Lapointe Anthony Gregg	Common Stock	Grant	Acquire A	No	No	0	25,000	0	50,000
20 May 22	Lapointe Anthony Gregg	Stock Option Common Stock	Grant	Acquire A	No	No	2.01	30,000	60.3K	30,000
20 May 22	Lyons Gary A	Common Stock	Grant	Acquire A	No	No	0	25,000	0	50,000
20 May 22	Lyons Gary A	Stock Option Common Stock	Grant	Acquire A	No	No	2.01	30,000	60.3K	30,000
20 May 22	Hannah Alison L.	Common Stock	Grant	Acquire A	No	No	0	25,000	0	31,250
20 May 22	Hannah Alison L.	Stock Option Common Stock	Grant	Acquire A	No	No	2.01	30,000	60.3K	30,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

RIGL institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	168	165	+1.8%
Opened positions	20	26	-23.1%
Closed positions	17	28	-39.3%
Increased positions	51	43	+18.6%
Reduced positions	55	56	-1.8%

13F shares	Current	Prev Q	Change
Total value	410.06M	461M	-11.1%
Total shares	136.64M	139.14M	-1.8%
Total puts	140.5K	288.7K	-51.3%
Total calls	312.9K	254K	+23.2%
Total put/call ratio	0.4	1.1	-60.5%

Largest owners	Shares	Value	Change
FMR	24.18M	$72.3M	-1.6%
BLK Blackrock	16.57M	$49.56M	+0.1%
Vanguard	9.13M	$27.31M	+1.2%
STT State Street	7.52M	$22.5M	-12.2%
IVZ Invesco	5.16M	$15.44M	-0.0%
Rock Springs Capital Management	4.92M	$14.72M	+1.3%
Lord, Abbett & Co.	4.41M	$13.19M	+1.8%
Nuveen Asset Management	4.15M	$13.39M	-8.1%
Great Point Partners	4M	$11.96M	-20.0%
Citadel Advisors	3.97M	$11.86M	+180.3%

Largest transactions	Shares	Bought/sold	Change
Citadel Advisors	3.97M	+2.55M	+180.3%
Millennium Management	2.5M	-2.05M	-45.0%
Adage Capital Partners GP, L.L.C.	1.9M	+1.81M	+1900.0%
Ikarian Capital	2.14M	+1.7M	+386.4%
Tamarack Advisers	3.25M	-1.25M	-27.8%
GS Goldman Sachs	626.67K	-1.16M	-64.9%
HealthInvest Partners AB	0	-1.09M	EXIT
STT State Street	7.52M	-1.04M	-12.2%
Great Point Partners	4M	-1M	-20.0%
Sio Capital Management	0	-913.62K	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

AMGEN • Curis • Novartis • Apellis Pharmaceuticals • Argen X SE • Kronos Bio • Immunovant

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: Annora, calendar, Caribbean, Circuit, combat, delisted, delisting, distraction, dyspnea, exclusionary, foreclose, Forma, grace, Hetero, inflation, isocitrate, Jersey, Knight, Latin, letter, lien, Mexico, mutated, Nasdaq, olutasidenib, path, pathophysiology, PDUFA, penalizing, pyrexia, regain, revealing, SA, SOFR, sublicensing, synergistic, thethird, unascertainable, unasserted, USA, vi, vigorously, visit, wake

Removed: begun, enrolling, HS, Incrementally, maintained, marketplace, palmoplantar, PPP, presidential, remained, sNDA, suppurativa, switch, topline

From filing 10-Q 2022 Q2

Financial reports

View all